Verge Genomics Announced A Four-Year Collaboration With Alexion, A Unit Of AstraZeneca For Drug Targets For Rare Neurodegenerative, Neuromuscular Diseases; Verge Will Receive Up To $42M Upfront With A Potential Deal Value Of $840M Plus Royalties
Portfolio Pulse from Benzinga Newsdesk
Verge Genomics has announced a four-year collaboration with Alexion, a unit of AstraZeneca, to develop drug targets for rare neurodegenerative and neuromuscular diseases. Verge will receive up to $42M upfront with a potential deal value of $840M plus royalties.
September 08, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's unit Alexion is partnering with Verge Genomics for drug development, potentially increasing AstraZeneca's portfolio and revenues.
The partnership with Verge Genomics could lead to the development of new drugs, potentially expanding AstraZeneca's portfolio and increasing its revenues. The upfront payment of $42M and potential deal value of $840M indicates a significant investment and potential return for AstraZeneca.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100